Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Cross-resistance between targeted therapy and immunotherapy
Acquired resistance to BRAF and MEK inhibitors in melanoma confers cross-resistance to immune-checkpoint blockade by fostering a cancer cell–instructed immunoevasive tumor microenvironment. The hourglass represents the time before therapy and after relapse on therapy, and the bottleneck imposed by targeted therapy that ultimately selects for cross-resistant clones.
The Biden administration has proposed a new agency to drive innovation in health research, including cancer. The focus on cancer and accelerated development is welcome, but for the time being, whether and how these plans will materialize is less clear.
Institutional clinical data repositories provide a depth and consistency of data elements that is difficult to match even with data pooled from diverse sources. A study now demonstrates how real-world data and clinical encounters can be captured in an integrated ‘data story’ to enable continuous learning and hypothesis generation in oncology.
Immuno-oncology approaches have shown little efficacy against high-grade glioma, a devastating manifestation of brain cancer. A new study now finds a metabolic vulnerability in IDH1-mutant glioma that can be targeted to reprogram tumor-infiltrating macrophages and create a tumor microenvironment that is more responsive to immune-checkpoint therapy.
Pasha and Turner review recent insights into the role of intratumoral heterogeneity in therapeutic resistance in metastatic breast cancer and discuss forward-looking strategies to overcome this hurdle.
Obenauf and colleagues report that acquired resistance to BRAF and MEK inhibitors in melanoma confers cross-resistance to immune checkpoint blockade by fostering a cancer cell–instructed, immune-evasive tumor microenvironment.
Morin and colleagues develop a data-integration framework capable of performing continuous learning from electronic health records on clinical, social and demographic data collected over a decade to estimate pan-cancer survival prognosis.
Platten and colleagues find that tryptophan metabolism by myeloid cells contributes to immunosuppressive microenvironment uniquely in IDH-mutant gliomas, which can be overcome by inhibiting this pathway in murine tumor models.
Kharas and colleagues identify the RNA-binding proteins RBMX and RBMXL1 as AML tumor promoters that alter chromatin compaction and hence cell survival via transcriptional regulation of the heterochromatin protein encoded by CBX5.
Wu and colleagues develop a barcoding tool, ClonMapper, which permits single-cell lineage tracing and clonal isolation and demonstrate its utility to study clonal dynamics in human CLL cells in the context of chemotherapy treatment and resistance.